MarkWilsonBrunvandMD

PubMed

• 4 citations
  Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
  Tycel Phillips, Mark Brunvand, Andy I. Chen, James Essell, Annalisa Chiappella
  American Journal of Hematology. 2021-11-03
• 5 citations
  Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
  Mark W. Brunvand, John Carson
  Hematological Oncology. 2018-02-01
• 56 citations
  Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
  Ranjana H. Advani, Daniel Lebovic, Andy I. Chen, Mark Brunvand, Andre Goy
  Clinical Cancer Research. 2017-03-01

Journal Articles

• Amyloidosis Relapsing After Autologous Stem Cell Transplantation Treated With Bortezomib: Normalization of Detectable Serum Free Light Chains and Reversal of Tissue Da...  
  Brunvand, MW, Bitter, M, Haematologica, 1/1/2010
• Relationship of Reconstituted Adaptive and Innate Cytomegalovirus (CMV)–Specific Immune Responses with CMV Viremia in Hematopoietic Stem Cell Transplant Recipients  
  Michelle A. Barron, Dexiang Gao, Kathryn L. Springer, Julie A. Patterson, Mark W. Brunvand, Peter A. McSweeney, Chang Zeng, Anna E. Barón, and Adriana Weinberg, Clinical Infectious Diseases, 1/15/2009
• Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase  
  Kantagjian, H.M., Larson, R.A., Guilhot, F., et al., Cancer, 1/1/2009
• Frequency of major cytogenetic responses to Imatinib or interferon Alfa plus cytarabine in newly diagnosed chronic myeloid leukemia  
  Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z. et al., New England Journal of Medicine, 1/1/2003
• Imatinib Compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia  
  O’Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochlaus, A., Hughes, T., Lechener, K., Nielsen, ..., New England Journal of Medicine, 1/1/2003
• T cell priming enhances IL-4 gene expression by increasing nuclear factor of activated T cells  
  Cron, RQ, Bort, SJ, Wang, Y, Brunvand, MW, Lewis, DB, J. Immunol., 1/1/1999
• Outcomes among 562 recipients of placental-blood transplants from unrelated donors  
  Rubinstein, P., C. Carrier, A. Scaradavou, J. Kurtzberg, J. Adamson, A. R. Migliaccio, R. L. Berkowitz, M. Cabbad, N. L. Dobrila, P. E. Taylor, R. E. Rosenfield, and C..., New England Journal Of Medicine, 1/1/1998
• High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral ...  
  Bensinger WI, Soll E, Weaver CH, Rowley SD, Appelbaum FR, Lilleby K, Clift RA, Gooley TA, Press OW, Fefer A, Storb R, Sanders JE, Martin PL, Chauncey T, Maziarz RT, Zu..., Bone Marrow Transplantation, 1/1/1996
• High-dose fractionated total body irradiation, etoposide and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma  
  Weaver, CH, Petersen, FB, Appelbaum, FR, Bensinger, WI, Press, O, Martin, P, Sandmaier, B, Deeg, HJ, Hansen, JA, Rowley, S, Benyunes, K, Chauncey, T, Fefer, A, Hackman..., J. Clin. Oncol., 1/1/1994
• Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies  
  Weaver, CH, Bensinger, WI, Appelbaum, FR, Lilleby, K, Sandmaier, B, Brunvand, M, Rowley, S, Petersdorf, S, Rivkin, S, Gooley, T, Weiden, P, Zuckerman, N, Montgomery, P..., Bone Marrow Transplantation, 1/1/1994
• Induction of alloantigen specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB-1  
  Tan, P, Anasetti, C, Hansen, JA, Melrose, J, Bradshaw, J, Ledbetter, JA, Linsley, P, J. Exp. Med., 1/1/1993
• In vivo footprinting of the human IL-2 gene reveals a nuclear factor bound to the transcription start site in resting T cells  
  Krumm, A, Groudine, M, Nucleic Acids Research, 1/1/1993
• The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region  
  Krumm, A, Meulia, T, Groudine, M, Genes & Development, 1/1/1992
• Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T lymphocyte subset ratios during treatment for early stage breast carcinoma  
  Collins, C, Livingston, RB, Raghu, G, Cancer, 1/1/1991
• Chronic recurrent goodpasture’s syndrome  
  Mehler, PS, Hutt, MP, Anderson RJ, Am J Med, 1/1/1987
• Join now to see all

Books/Book Chapters

• Oncology Nursing Secrets 
  Chapter: Bone Marrow Transplantation 
  Becker, Carolyn, RN, NP, Brunvand, Mark, MDEditors: Rose Ann Gates, RN, MSN, CNS, NP, PhD, AOCN; Regina Fink, RN, PhD, FAAN, AOCN.Edition 3rd,

Abstracts/Posters

• Safety and Efficacy from a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocyt...
  Ian Flinn, Michael Choi, Martin J.S. Dyer, John Gribben, Peter Hillmen, Jeffrey Jones, Jeffrey Sharman, Yan Li, Mehrdad Mobasher, Gregory Vosganian, Thomas J. Kipps, ASH, 1/1/2015
• Preliminary results of a Phase 1b study combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic ...
  Ian Flinn, Martin J.S. Dyer, Peter Hillmen, Jeffrey Jones, Yan Li, Mostafa Elhamy, Gregory Vosganian, Jane Huang, Thomas J. Kipps, Blood, 1/1/2014
• Phase I Study of the Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S with or without Rituximab (RTX) in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Non-H...
  Ranjana Advani, Andy Chen, Daniel Lebovic, Andre Goy, Julie Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Akiko Chai, Yu-Waye Chu, Bruce D. Cheson, The 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 1/19/2013
• Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory...
  Andy I. Chen, Daniel Lebovic, Andre Goy, Julie E. Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Akiko Chai, Yu-Waye Chu, and Bruce D. Cheson, Blood, 1/1/2013
• Final Results of a Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin (DCDT2980S) with or without Rituximab in Patients with Relapsed or Refrac...
  Ranjana Advani, Andy Chen, Daniel Lebovic, Andre Goy, Julie Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Akiko Chai, Yu-Waye Chu, Bruce D. Cheson, Blood, 1/1/2013
• Hematopoietic Cell Transplantation After Reduced Intensity Conditioning for Severe Paroxysmal Nocturnal Hemoglobinuria
  Rafic Farah, Georg Franke, MD, Tara B. Gregory, MD, Thoralf Lang, Rainer Storb, MD, Robert P. Witherspoon, Blood, 1/1/2011
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-M...
  Tara K. Gregory, M.D., Peter A. McSweeney, M.D., Jeffery V. Matous, M.D., Scott I. Bearman, M.D. and Michael B. Maris, M.D., Blood, 1/1/2009
• A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation between Clinical Responses and...
  Jonathan W. Friedberg, Julie M. Vose, Brad Kahl, Andre Goy, Yvette Kasamon, Jing Li, William Ho, Bruce D. Cheson, Blood, 1/1/2009
• Results of a randomized phase II trial of pegfilgrastim versus filgrastim to treat neutropenia post-autologous peripheral blood stem cell transplant (PBSCT) in patient...
  Rifkin, R, Beveridge,R, Spitzer, G, Orloff, G, Mandanas, R, McGaughey, D, Zhan, F, Boehm, KA, Asmar, L, Blood, 1/1/2007
• CD20(+) Non-Hodgkin Lymphoma patients treated with radio-immunotherapy for failure to mobilize or relapse after autologous stem cell transplant
  Brunvand, MW, Pan-Pacific Lymphoma Conference, 1/1/2007
• Preliminary data on once-daily IV busulfan at 3.2 mg/kg/day indicate that it is safe as a component of the conditioning regimen for hematolpoietic stem cell transplant...
  Rifkin, R, Matous, JV, McSweeney, P, Bearman, S, Blood, 1/1/2004
• Gemtuzumab Ozogamicin (Mylotarg) as a single agent to evaluate safety and determine maximum tolerated dose (MTD) in post hemopoietic stem cell transplant patients with...
  Sievers, EL, Spielberger, R, Feingold, J, Culleton, V, Armstrong, P, Resnick, GD, Roth, DC, Blood, 1/1/2002
• Phase I/II study of combination of high-dose therapy with busulfan, thiotepa, and total body irradiation (TBI) for the treatment of aggressive multiple myeloma
  Leis, JF, Hansen, KS, Fleming, WH, Curtin, PT, Manashe, JI, Gruenberg, DR, Seelig, FA, Kratz, AC, Stepan, DE, Lanier, KS, Kerr, MM, Subbiah, N, Hansen, LK, Maziarz, RT, Blood, 1/1/2000
• The role of NFAT in enhanced IL-4 gene expression by effector T cells
  Cron, RQ, Bort, SJ, Wang, Y, Lewis, DB, Arthritis Foundation Research Conference, 1/1/1996
• The IL-2 promoter is bound by nuclear factors in nontransformed human cord blood T cells and cooperative binding of nuclear factors is seen during T cell activation
  Nash, R, Lewis, D, Storb, R, Blood, 1/1/1994
• In vivo footprint of IL-2 promoter in unstimulated and mitogen stimulated NFAT-Z Jurkat T lymphocytes
  Brunvand, MW, Proceedings of AAI, 1/1/1993
• In vivo footprint of the IL-2 promoter in NFAT-Z Jurkat T lymphocytes: activation specific cis-elements
  Brunvand, MW, Blood, 1/1/1992
• Jurkat T cell nuclear factor binds the interleukin-2 promoter region and is important for in vitro transcription
  Brunvand, MW, Siebenlist, U, J Cell Biochem, 1/1/1988
• The interleukin-2 gene: in vitro transcription and interaction with a nuclear factor
  Brunvand, MW, Siebenlist, U, Clinical Research, 1/1/1988
• Cis control regions in the interleukin-2 promoter
  Brunvand, MW, Siebenlist, U, FASEB, 1/1/1987
• Propranolol Increases the Size of Doxorubicin Extravasation Injury in Mice
  Koepler, H, Robinson,WA, et al, National Student Research Forum, 1/1/1982
• Join now to see all